CJC-1295/Ipamorelin effects include higher growth hormone pulses, IGF-1 changes, and reported side effects. See what research shows and what is unknown.
CJC-1295 and ipamorelin are two different growth hormone secretagogues, and their combined effects are usually described as a larger and longer-lasting rise in growth hormone and IGF-1 than either peptide produces alone. CJC-1295 acts as a growth hormone–releasing hormone (GHRH) analog, while ipamorelin mimics ghrelin at the growth hormone secretagogue receptor. Neither peptide is FDA-approved for human use in the United States, and no large randomized trial has tested the combination in people.
How CJC-1295 and Ipamorelin Work Together
Growth hormone leaves the pituitary in pulses, and these two peptides act on separate receptors that feed into the same pulse. CJC-1295 increases pulse amplitude through GHRH receptors, while ipamorelin triggers the pulse through ghrelin receptors.
Because the mechanisms are distinct, researchers describe the pairing as additive or synergistic. Animal studies of ipamorelin show selective growth hormone release with little effect on cortisol or prolactin, which is one reason it is often studied alongside a GHRH analog.
| Peptide | Receptor target | Approximate half-life | Primary reported effect |
|---|---|---|---|
| CJC-1295 with DAC | GHRH receptor | About 6–8 days | Sustained growth hormone and IGF-1 elevation |
| CJC-1295 without DAC | GHRH receptor | About 30 minutes | Short, natural-style growth hormone pulse |
| Ipamorelin | Ghrelin / GHS-R1a | About 2 hours | Selective growth hormone pulse with minimal cortisol rise |
No FDA-approved CJC-1295/ipamorelin product exists, and the combined effects in humans have not been established in controlled clinical trials.
Reported Effects of CJC-1295 and Ipamorelin
Most claims about what the combination does come from animal data, small single-compound human studies, and user anecdotes rather than controlled trials. The effects most often reported include:
- Higher growth hormone pulse amplitude, especially during sleep.
- Rising IGF-1 levels, which is the downstream marker researchers measure most often.
- Reports of deeper sleep and faster perceived recovery from training.
- Increased appetite, particularly with ipamorelin.
- Water retention, joint stiffness, and mild numbness or tingling in the hands.
The clearest human data come from a small 2006 study in healthy adults, where a single dose of CJC-1295 with DAC raised growth hormone and IGF-1 for up to six days. That study did not include ipamorelin and was not designed to assess long-term safety.
Reported CJC-1295/ipamorelin effects in humans remain largely anecdotal, and none of them are established as a treatment for any medical condition.
CJC-1295 With DAC vs Without DAC
People searching cjc-1295 with dac vs ipamorelin are usually comparing two substances that behave very differently: a long-acting GHRH analog and a short-acting ghrelin mimetic. The “DAC” version is modified to bind albumin, which stretches its activity over days instead of minutes.
| Feature | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Half-life | About 6–8 days | About 30 minutes |
| IGF-1 response | Sustained elevation in the one small human study | Brief, pulse-like elevation |
| Typical research interest | Long-acting baseline support | Pairing with ipamorelin for pulse timing |
| Main concern | Prolonged IGF-1 exposure | Frequent injection schedules |
Many vendors sell a blend labeled cjc-1295 without dac 5mg ipamorelin 5mg, which is why the two names appear together so often in search results and forum threads. In practice, cjc 1295 dac reconstitution means adding bacteriostatic water to a lyophilized powder, and reported cjc 1295 dac cycle length in user communities typically runs eight to twelve weeks, though no trial has validated that schedule or its safety.
A frequent question is can you take igf-1 lr3 and cjc-1295 together, since IGF-1 LR3 acts downstream of growth hormone while CJC-1295 acts upstream. Stacking both raises the theoretical risk of pushing IGF-1 well above normal ranges, and no human study has examined that combination.
Side Effects and Safety Considerations
Side effects linked to growth hormone secretagogues are usually mild but worth taking seriously.
- Injection-site redness, pain, or swelling.
- Fluid retention, puffiness, and joint discomfort.
- Headache, flushing, and a brief feeling of warmth after injection.
- Increased hunger, which can work against body composition goals.
- Possible blood sugar changes, since growth hormone and IGF-1 both influence insulin sensitivity.
Because IGF-1 can promote cell growth, there is a theoretical concern about stimulating existing tumors or abnormal tissue. People with a history of cancer, diabetes, or pituitary disease should avoid these compounds unless a physician specifically recommends otherwise.
Unregulated peptides also carry a purity problem. Independent testing has repeatedly found that research-grade vials can be underdosed, mislabeled, or contaminated, and that risk is higher for products sold without a prescription.
What the Evidence Does and Does Not Show
What the evidence shows: CJC-1295 raises growth hormone and IGF-1 in one small human study, ipamorelin releases growth hormone selectively in animal models, and the two act on different receptors. What the evidence does not show: whether the combination is safe or effective in humans over weeks or months.
There are no published long-term human safety trials for this pairing, no established dose, and no regulatory oversight of the products sold online. Anyone considering these peptides should talk with a licensed healthcare professional and treat marketing claims as unverified.
Frequently Asked Questions
What effects does CJC-1295/ipamorelin actually have?
The reported effects are a stronger and longer growth hormone pulse plus a rise in IGF-1, along with anecdotal reports of better sleep, faster recovery, and increased appetite. These effects are mostly documented in animal studies, one small human study of CJC-1295 alone, and user reports. No controlled human trial has measured the combination.
How long does it take for CJC-1295 and ipamorelin to work?
User reports often describe noticeable changes in sleep or recovery within one to two weeks, while IGF-1 shifts can take several weeks to appear on bloodwork. CJC-1295 with DAC stays active for days after a single dose, while CJC-1295 without DAC and ipamorelin clear within hours. None of these timelines come from controlled human trials of the combination.
Is CJC-1295/ipamorelin FDA approved in the United States?
No. Neither CJC-1295 nor ipamorelin is FDA-approved for human use, and both are sold as research chemicals rather than prescription drugs. That means there is no approved dose, no required purity testing, and no regulated supply chain. Anyone with a medical concern about growth hormone or IGF-1 levels should see a licensed healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.